Zephyr Energy says 2024 was another strong year for its Williston Basin assets in North Dakota, averaging 1,149 barrels per day. In Utah, well-completion at its Paradox project starts next week, with testing results expected by mid-to-late April.
KEFI Gold and Copper says its Tulu Kapi project in Ethiopia is progressing as planned, with key financing approvals expected in the coming weeks. An equity raise at the subsidiary level remains on schedule while the $240 million finance package is also advancing.
Hemogenyx Pharmaceuticals has secured £709,200 in new investment from an institutional backer to support clinical trials for its experimental leukaemia treatment. The funding will help advance patient recruitment, with early results determining the next phase of testing.
Synairgen is set to leave London’s AIM market after falling short of fundraising targets. The company says going private will cut costs and help it focus on its long-term strategy.
Solvonis Therapeutics has appointed Dr Renata Crome as an independent director, bringing 40 years of experience in drug development and regulatory approval. She spent 30 years at Roche, helping advance over 100 therapies, including Avastin and Tamiflu.
